Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS May Take Lead In Federal Compounding Oversight After Court Ruling

Executive Summary

The Centers for Medicare & Medicaid Services may serve as a stronger regulatory presence for pharmacy compounders in light of a recent federal court decision rejecting FDA's enforcement authority over the practice
Advertisement

Related Content

Wyeth Loses Citizen Petition Battle But Wins War Over Compounded Hormones
Wyeth Loses Citizen Petition Battle But Wins War Over Compounded Hormones
Avastin Widespread Availability For Eye Use May Depend On FDA Clearance
Avastin Widespread Availability For Eye Use May Depend On FDA Clearance
Rx Compliance Enforcement Is Moving Away From “FDA” Cases, Sheehan Says
Rx Compliance Enforcement Is Moving Away From “FDA” Cases, Sheehan Says
Wyeth Urges Halt to Hormone Compounding, Questioning Its Safety
Wyeth Urges Halt to Hormone Compounding, Questioning Its Safety
Advertisement
UsernamePublicRestriction

Register

PS047550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel